Halozyme Therapeutics (NASDAQ:HALO) Reaches New 52-Week High – Should You Buy?

Halozyme Therapeutics, Inc. (NASDAQ:HALO) shares reached a new 52-week high during mid-day trading on Thursday. The stock traded as high as $119.21 and last traded at $116.82, with a volume of 3,768,940 shares changing hands. The stock had previously closed at $109.62.

More Halozyme Therapeutics News

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Zacks upgraded HALO from “hold” to “strong buy,” citing strong price performance and favorable earnings trends. The upgrade helped reinforce investor momentum. 5 Stocks to Buy Using the Relative Price Strength Strategy
• Positive Sentiment: H.C. Wainwright reaffirmed its Buy rating on Halozyme, signaling continued confidence in the company’s growth outlook and commercial execution. H.C. Wainwright Reaffirms Their Buy Rating on Halozyme
• Positive Sentiment: TD Cowen projected substantial price appreciation for HALO, adding to the positive analyst sentiment surrounding the stock. TD Cowen Forecasts Strong Price Appreciation for Halozyme
• Positive Sentiment: Halozyme was highlighted in multiple stock-selection reports as a relative-strength and top-ranked nontechnology Nasdaq pick, based on strong price performance and rising earnings estimates. Buy 5 Top-Ranked Non-Tech Nasdaq Stocks
• Neutral Sentiment: An expanded agreement with argenx could improve Halozyme’s long-term royalty and licensing opportunity, but investors are weighing the deal’s ultimate financial contribution and execution risks. Is Expanded Argenx Deal Altering the Investment Case for Halozyme?

Analysts Set New Price Targets

HALO has been the subject of several research reports. Leerink Partners upgraded shares of Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and lifted their price objective for the stock from $83.00 to $110.00 in a research note on Friday, August 7th. JPMorgan Chase & Co. upped their target price on Halozyme Therapeutics from $70.00 to $78.00 and gave the company a “neutral” rating in a research report on Thursday, October 8th. TD Cowen raised their target price on Halozyme Therapeutics from $105.00 to $130.00 and gave the stock a “buy” rating in a research note on Tuesday. Stifel Nicolaus set a $130.00 target price on Halozyme Therapeutics in a research note on Friday. Finally, HC Wainwright lifted their price target on Halozyme Therapeutics from $115.00 to $130.00 and gave the stock a “buy” rating in a research report on Wednesday, October 7th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $99.55.

Halozyme Therapeutics Price Performance

The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50. The stock has a 50-day moving average price of $109.06 and a 200 day moving average price of $84.92. The stock has a market capitalization of $13.83 billion, a price-to-earnings ratio of 24.65, a PEG ratio of 0.46 and a beta of 0.88.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, beating the consensus estimate of $1.79 by $0.49. The company had revenue of $481.00 million for the quarter, compared to analyst estimates of $402.28 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%. Halozyme Therapeutics’s quarterly revenue was up 47.7% compared to the same quarter last year. During the same period last year, the company earned $1.54 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, equities research analysts expect that Halozyme Therapeutics, Inc. will post 8.31 earnings per share for the current year.

Insider Buying and Selling

In other Halozyme Therapeutics news, Director Matthew Posard sold 5,230 shares of the business’s stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $108.54, for a total transaction of $567,664.20. Following the completion of the sale, the director directly owned 53,609 shares in the company, valued at approximately $5,818,720.86. The trade was a 8.89% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction dated Thursday, October 8th. The shares were sold at an average price of $109.40, for a total transaction of $2,188,000.00. Following the sale, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at approximately $83,995,132. This represents a 2.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 125,852 shares of company stock worth $13,538,046. Insiders own 2.50% of the company’s stock.

Institutional Investors Weigh In On Halozyme Therapeutics

A number of institutional investors have recently modified their holdings of HALO. Horizon Investment Services LLC acquired a new stake in Halozyme Therapeutics in the second quarter valued at approximately $2,254,000. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in Halozyme Therapeutics in the second quarter valued at approximately $1,025,000. Great Lakes Advisors LLC acquired a new stake in Halozyme Therapeutics during the second quarter worth approximately $2,821,000. Chase Investment Counsel Corp purchased a new stake in shares of Halozyme Therapeutics during the 2nd quarter worth approximately $2,035,000. Finally, WINTON GROUP Ltd boosted its stake in Halozyme Therapeutics by 704.6% in the second quarter. WINTON GROUP Ltd now owns 60,348 shares of the biopharmaceutical company’s stock valued at $4,723,000 after acquiring an additional 52,848 shares in the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses recombinant human hyaluronidase to temporarily modify tissue beneath the skin, allowing certain drugs and biologics that are traditionally delivered by intravenous infusion to be administered by subcutaneous injection.

Halozyme licenses its technology to pharmaceutical and biotechnology companies, which incorporate it into their own therapies.